Aflibercept biosimilar (Celltrion)

阿柏西普生物类似药 (Celltrion)

Report date: 2025/12/05 14:12:23

Base Information

Drug NameAflibercept biosimilar (Celltrion)
Drug Alias NameEydenzeltCT-P42
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionVascular endothelial growth factor A inhibitorsPlacental Growth Factor inhibitors
TargetsVascular endothelial growth factor APlacental Growth Factor
Therapy Area/IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[8] 
Global Approved IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[8] 
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2024/05/30
Country/TerritoryCanadaUnited StatesSlovakia +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrion Healthcare Hungary KftCelltrion IncKukje Pharma Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A